Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
peripherally acting μ-opioid receptor antagonist |
| gptkbp:approvalYear |
2008
|
| gptkbp:ATCCode |
A06AH03
|
| gptkbp:blackBoxWarning |
true
|
| gptkbp:brand |
Entereg
|
| gptkbp:CASNumber |
170098-28-9
|
| gptkbp:contraindication |
patients who have taken therapeutic doses of opioids for more than 7 consecutive days prior to use
|
| gptkbp:developer |
Adolor Corporation
|
| gptkbp:eliminationHalfLife |
10-17 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C25H32N2O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alvimopan
|
| gptkbp:KEGGID |
D03141
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
blocks peripheral μ-opioid receptors
|
| gptkbp:metabolism |
gptkb:gut_flora
|
| gptkbp:notCrossBloodBrainBarrier |
true
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:proteinBinding |
80%
|
| gptkbp:PubChem_CID |
CHEMBL1201192
130574 148191 DB06274 |
| gptkbp:restrictedDistributionProgram |
Entereg Access Support and Education (E.A.S.E.)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
myocardial infarction risk (long-term use)
|
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
acceleration of gastrointestinal recovery after bowel resection
postoperative ileus |
| gptkbp:bfsParent |
gptkb:Opioids
|
| gptkbp:bfsLayer |
7
|